Form 4: Precigen Director Converts RSUs to Common Stock

Precigen Director Jeffrey B. Kindler converted 71,839 restricted stock units into common stock, increasing his direct beneficial ownership to 202,100 shares.

Summary

• Jeffrey B. Kindler, a Director of Precigen, Inc. (PGEN), acquired 71,839 shares of common stock.
• This acquisition resulted from the full vesting of restricted stock units (RSUs) on March 13, 2026.
• Each RSU represented a contingent right to receive one share of Precigen common stock.
• Following this transaction, Mr. Kindler directly beneficially owns 202,100 shares of Precigen common stock.
• The derivative securities (RSUs) had an exercise price of $0 and are now fully vested and converted.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine, expected insider transaction related to compensation. The increase in direct beneficial ownership by a director is generally a neutral to slightly positive signal, indicating continued alignment with shareholder interests.

Positives

• Director Jeffrey B. Kindler increased his direct beneficial ownership of Precigen common stock by 71,839 shares, indicating continued alignment with shareholder interests.
• The conversion of Restricted Stock Units (RSUs) into common stock at a $0 exercise price represents a non-cash compensation event for the director.

Negatives

• No direct negatives are apparent from this routine insider transaction filing.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that the conversion of Restricted Stock Units (RSUs) into common stock is a standard compensation practice for directors and executives in the biotechnology and pharmaceutical industries, aligning their interests with long-term company performance. This transaction reflects a routine vesting event rather than a discretionary purchase or sale.

Comparison to Industry Standards

• The vesting and conversion of RSUs at a $0 exercise price is a common form of equity compensation across various industries, including biotech, for directors and executives.
• This practice is consistent with compensation structures observed at comparable companies such as Regeneron Pharmaceuticals (REGN) or Amgen (AMGN), where equity awards are used to incentivize long-term commitment and performance.

Related Party Transactions

• The transaction involves a director of the company acquiring shares from the company as part of their compensation, which is a related party transaction.

Stakeholder Impact

• Shareholders: The increase in director ownership aligns the director's interests more closely with shareholders.

Key Dates

Recommendation

This Form 4 filing details a routine, expected vesting and conversion of Restricted Stock Units by a director. While it increases insider ownership, it does not provide new fundamental information about the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Investors should consider this a neutral event in the context of their broader investment thesis for Precigen.

Keywords

Precigen, PGEN, Form 4, Insider Transaction, Restricted Stock Units, RSU conversion, Director ownership, Jeffrey B. Kindler, Beneficial ownership